IDEAYA Presents Early Data on Novel Cancer Therapies at AACR
Event summary
- IDEAYA Biosciences will present preclinical data at the AACR Annual Meeting (April 17-22, 2026) for three clinical-stage programs: IDE034, IDE574, and IDE892.
- IDE034 is a bi-specific ADC targeting PTK7 and B7-H3; IDE574 inhibits KAT6/7; IDE892 inhibits PRMT5 and is designed for MTAP-deleted cancers in combination with IDE397.
- Phase 1 clinical trials are underway to assess safety, tolerability, pharmacokinetics, and efficacy across lung, colorectal, pancreatic, breast, and prostate cancer indications.
- The poster presentations will be available on IDEAYA's website following the meeting.
The big picture
IDEAYA's focus on first-in-class therapies targeting DNA damage repair and epigenetic pathways reflects a broader trend in oncology towards precision medicine and overcoming drug resistance. The company’s pipeline, while early-stage, represents a significant investment in novel therapeutic modalities, particularly ADCs and targeted small molecules. Success hinges on demonstrating clinical efficacy and navigating the inherent risks of early-stage drug development.
What we're watching
- Clinical Efficacy
- The initial Phase 1 data presented at AACR will be crucial in determining the therapeutic potential of these programs, particularly given the broad range of cancer types being targeted.
- Combination Strategy
- The planned combination of IDE892 with IDE397 highlights a strategic focus on synergistic therapies; success will depend on demonstrating a clear benefit beyond monotherapy.
- Biomarker Selection
- IDE574’s efficacy is tied to biomarker-selected indications, suggesting that patient stratification will be critical for demonstrating clinical benefit and guiding future development.
Related topics